FDA Scientists Warn About Bleeding Risk of Bayer's Blood-Thinning Drug

Email this article to a friend

Printable Version

Articles Related to This Article: • FDA Scientists Accuse Own Administration of Corruption, Intimidation and Scientific Censorship • FDA's own scientists report pattern of intimidation, censorship and scientific fraud that undermines public safety • FDA Scientists Revolt Against Corrupt Food and Drug Administration Officials Support NaturalNews advertisers - Advertise with NaturalNews Help support NaturalNews with health books and educational programs from Truth Publishing: • Swine Flu Advanced Preparedness • 8 Weeks to Vibrant Health • Raw In Ten Minutes (recipes) • How to Halt Diabetes in 25 Days ... and much more.

(NaturalNews) The FDA has publicly released documents from science reviewers expressing concern over the blood-thinning drug rivaroxaban, marketed by Bayer AG and Johnson & Johnson (J&J) as Xarelto in Canada and Europe. The drug has yet to receive regulatory approval in the United States, but an application is pending.

The pill, introduced as a competitor to Sanofi-Aventis' injectable drug Lovenox (enoxaparin), is indicated for once-a-day short term use in order to prevent blood clots following hip- or knee-replacement surgeries. A series of randomized clinical trials (RECORD) on a total of 6,183 participants found Xarelto to be just effective as Lovenox, if not more so, but also that it was twice as likely to cause bleeding.

"The evidence that administration of rivaroxaban (Xarelto) could lead to bleeding events in significantly more patients relative to enoxaparin amplifies [the] safety concern for rivaroxaban," FDA staff wrote.

Concerns have also been raised over the possibility that Xarelto might increase patients' risk of liver damage. One participant in the RECORD trials died of liver toxicity. FDA staff noted that more long-term studies would be needed to gain understanding of the drug's liver risks.

Two days after the agency released its scientists' concerns, an FDA advisory panel recommended approval of the drug for short-term use, and in Europe and Canada. The panel acknowledged that Xarelto is more likely to cause bleeding than Lovenox.

Approximately 800,000 hip- and knee-replacement surgeries take place in the United States every year, providing only a relatively small market for Xarelto or Lovenox. But analysts expect Bayer and J&J to eventually seek approval for long-term use of the drug for stroke prevention. According to analysts from Morgan Stanley, sales of Xarelto for hip- and knee-replacements will likely peak at $200 million per year, yet Bayer has projected eventual annual sales of $2.6 billion for all uses.

Sources for this story include: www.reuters.com.

Share

Get articles like this delivered to you FREE in our popular email newsletter

Related CounterThink Cartoons:

Related Articles: • FDA Scientists Accuse Own Administration of Corruption, Intimidation and Scientific Censorship • FDA's own scientists report pattern of intimidation, censorship and scientific fraud that undermines public safety • FDA Scientists Revolt Against Corrupt Food and Drug Administration Officials	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/026523_FDA_scientists_Bayer_blood.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.NaturalNews.com/026523_FDA_scientists_Bayer_blood.html">FDA Scientists Warn About Bleeding Risk of Bayer's Blood-Thinning Drug</a>